Evidence map›Paper›PMID 29955515›Full record

ArticleThe mental health clinician2017

Psychiatric symptoms and synthetic cannabinoid use: Information for clinicians.

Gary Sweet, Sara Kim, Samuel Martin, Nicole B Washington, Nancy Brahm

Open access · goldAbstract read
In one paragraph

Article in The mental health clinician, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Gary SweetPGY-2 Psychiatric Pharmacy Resident, Veterans Affairs Health System of Western NY, Buffalo, New York. Previously: Department of Clinical Pharmacy Services, Saint John Medical Center, Tulsa, Oklahoma.ORCID 0000-0002-1309-2616
Sara KimPGY-1 Pharmacy Resident, Oklahoma State University Medical Center, Tulsa, Oklahoma. Previously: University of Oklahoma College of Pharmacy, Tulsa, Oklahoma.ORCID 0000-0002-5117-1366
Samuel MartinAssistant Professor of Psychiatry, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma. Previously: Department of Psychiatry, University of Oklahoma School of Community Medicine, Tulsa, Oklahoma.ORCID 0000-0003-2802-7267
Nicole B WashingtonMedical Director, Crisis Care Center, Family and Children's Services, Tulsa, Oklahoma.ORCID 0000-0002-8879-193X
Nancy BrahmClinical Professor, University of Oklahoma College of Pharmacy, Tulsa, Oklahoma, Nancy-Brahm@ouhsc.edu.ORCID 0000-0001-6812-6855
Family & Children’s Services · USOklahoma State University Center for Health Sciences · USOklahoma State University Medical Center · USSt. John Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLimited treatment information is available when patients present with psychotic symptoms secondary to synthetic cannabinoid (SC) use. Symptoms associated with use are often indistinguishable from those encountered with a primary mental illness and also include aggression, confusion, and anxiety. For these patients, clinicians rely on physical presentation, symptom(s) onset, and episode duration when evaluating patients. PATIENT HISTORY: An adult man was involuntarily admitted to inpatient status secondary to reports of bizarre behaviors that included paranoia and psychomotor agitation. Because of the severity of the symptoms, he was unable to participate in the admission assessment. On day 2, he reported having smoked a substance provided by a friend. In addition, he admitted to previous SC use on 3 occasions, with each occasion resulting in an involuntary admission to inpatient status. The course of this admission was unremarkable.

conclusionsA brief overview of psychiatric signs and symptoms of SC use and information to help clinicians are included. The presentation of psychotic symptoms secondary to SC may be consistent with those of psychosis or other substances of abuse. Because of the variability in the symptoms produced by SC use, clinicians are encouraged to consider SC use in the diagnostic evaluation.

Indexed as

cannabinoidcannabisherbal incenseintoxicationK2legal highmarijuana alternativepsychosis

Identifiers

PMID29955515
PMCPMC6007529
OpenAlexW2730292686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.